CoChat

Successful Regional Delivery and Long-term Expression of a Dystrophin Gene in Canine Muscular Dystrophy: A Preclinical Model for Human Therapies

Open access
Wang, Zejing, Storb, Rainer, Halbert, Christine L, Banks, Glen B., Butts, Tiffany M., Finn, Eric E., Allen, James M., Miller, A. Dusty, Chamberlain, Jeffrey S., Tapscott, Stephen J. · 2012 · Molecular Therapy
Cited by 78

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Duchenne muscular dystrophy (DMD) is a fatal, X-linked muscle disease caused by mutations in the dystrophin gene. Adeno-associated viral (AAV) vector-mediated gene replacement strategies hold promise as a treatment. Studies in animal models and human trials suggested that immune responses to AAV capsid proteins and transgene products prevented efficient gene therapy. In this study, we used widespread intramuscular (i.m.) injection to deliver AAV6-canine micro-dystrophin (c-µdys) throughout a group of skeletal muscles in dystrophic dogs given a brief course of commonly used immunosuppressants. Robust c-µdys expression was obtained for at least two years and was associated with molecular reconstitution of the dystrophin-glycoprotein complex (DGC) at the muscle membrane. Importantly, c-µdys expression was maintained for at least 18 months after discontinuing immunosuppression. The results obtained in a relevant preclinical model of DMD demonstrate feasibility of widespread AAV-mediated muscle transduction and transgene expression in the presence of transient immunosuppression to achieve molecular reconstitution that can be directly translated to human trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2012.111

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 38

  1. Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol, 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
  2. Ahn, 1993, The structural and functional diversity of dystrophin, Nat Genet, 3, 283, 10.1038/ng0493-283 · DOI · Paper page
  3. Wang, 2009, Gene therapy in large animal models of muscular dystrophy, ILAR J, 50, 187, 10.1093/ilar.50.2.187 · DOI
  4. Mendell, 2009, Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins, Ann Neurol, 66, 290, 10.1002/ana.21732 · DOI · Paper page
  5. Wang, 2011, Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials, Front Microbiol, 2, 201, 10.3389/fmicb.2011.00201 · DOI · Paper page
  6. Hoffman, 2011, Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through, Am J Pathol, 179, 12, 10.1016/j.ajpath.2011.03.050 · DOI
  7. Aartsma-Rus, 2010, New insights in gene-derived therapy: the example of Duchenne muscular dystrophy, Ann N Y Acad Sci, 1214, 199, 10.1111/j.1749-6632.2010.05836.x · DOI
  8. Vilquin, 2011, Cell therapy for muscular dystrophies: advances and challenges, Curr Opin Organ Transplant, 16, 640, 10.1097/MOT.0b013e32834cfb70 · DOI
  9. Negroni, 2011, Current advances in cell therapy strategies for muscular dystrophies, Expert Opin Biol Ther, 11, 157, 10.1517/14712598.2011.542748 · DOI
  10. Palmieri, 2010, Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy, Pediatr Transplant, 14, 813, 10.1111/j.1399-3046.2010.01377.x · DOI
  11. Wang, 2007, Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy, Hum Gene Ther, 18, 18, 10.1089/hum.2006.093 · DOI · Paper page
  12. Yue, 2008, A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs, Mol Ther, 16, 1944, 10.1038/mt.2008.207 · DOI · Paper page
  13. Yuasa, 2007, Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products, Gene Ther, 14, 1249, 10.1038/sj.gt.3302984 · DOI
  14. Ohshima, 2009, Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle, Mol Ther, 17, 73, 10.1038/mt.2008.225 · DOI · Paper page
  15. Wang, 2010, Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging, Mol Ther, 18, 617, 10.1038/mt.2009.294 · DOI
  16. Wang, 2007, Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression, Mol Ther, 15, 1160, 10.1038/sj.mt.6300161 · DOI · Paper page
  17. Lapidos, 2004, The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma, Circ Res, 94, 1023, 10.1161/01.RES.0000126574.61061.25 · DOI · Paper page
  18. Ervasti, 1991, Membrane organization of the dystrophin-glycoprotein complex, Cell, 66, 1121, 10.1016/0092-8674(91)90035-W · DOI · Paper page
  19. Tidball, 1991, Force transmission across muscle cell membranes, J Biomech, 24, 43, 10.1016/0021-9290(91)90376-X · DOI · Paper page
  20. Tidball, 1991, Dystrophin is required for normal thin filament-membrane associations at myotendinous junctions, Am J Pathol, 138, 17
  21. Banks, 2010, The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins, PLoS Genet, 6, e1000958, 10.1371/journal.pgen.1000958 · DOI · Paper page
  22. Herson, 2011, A phase I dose-escalating study of AAV1–γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C, Mol Ther, 19, S20
  23. Kornegay, 2010, Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs, Mol Ther, 18, 1501, 10.1038/mt.2010.94 · DOI · Paper page
  24. Halbert, 2010, Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs, Mol Ther, 18, 1165, 10.1038/mt.2010.51 · DOI
  25. Shin, 2012, Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs, Hum Gene Ther, 23, 287, 10.1089/hum.2011.125 · DOI · Paper page
  26. Arnett, 2011, Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector, Front Microbiol, 2, 220, 10.3389/fmicb.2011.00220 · DOI
  27. Storb, 1997, Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation, Blood, 89, 3048, 10.1182/blood.V89.8.3048 · doi:10.1182/blood.v89.8.3048
  28. Yu, 1998, Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts, Blood, 91, 2581, 10.1182/blood.V91.7.2581 · doi:10.1182/blood.v91.7.2581
  29. Storb, 1973, Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone, Blood, 42, 601, 10.1182/blood.V42.4.601.601 · doi:10.1182/blood.v42.4.601.601
  30. Storb, 1974, Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum, J Immunol, 112, 1508, 10.4049/jimmunol.112.4.1508 · doi:10.4049/jimmunol.112.4.1508
  31. Storb, 1974, Treatment of established human graft-versus-host disease by antithymocyte globulin, Blood, 44, 56, 10.1182/blood.V44.1.57.57 · doi:10.1182/blood.v44.1.57.57
  32. Storb, 1994, Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia, Blood, 84, 941, 10.1182/blood.V84.3.941.941 · doi:10.1182/blood.v84.3.941.941
  33. Kahl, 2005, Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up, Br J Haematol, 130, 747, 10.1111/j.1365-2141.2005.05667.x · DOI
  34. Dell'Agnola, 2004, Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs, Blood, 104, 4311, 10.1182/blood-2004-06-2247 · DOI
  35. Blankinship, 2004, Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6, Mol Ther, 10, 671, 10.1016/j.ymthe.2004.07.016 · DOI · Paper page
  36. Rafael, 1996, Forced expression of dystrophin deletion constructs reveals structure-function correlations, J Cell Biol, 134, 93, 10.1083/jcb.134.1.93 · DOI · Paper page
  37. Banks, 2008, Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin, Hum Mol Genet, 17, 3975, 10.1093/hmg/ddn301 · DOI
  38. Halbert, 2006, Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors, Hum Gene Ther, 17, 440, 10.1089/hum.2006.17.440 · DOI · Paper page

Cited by

See all 78

Metadata

Authors
Wang, Z., Storb, R., Halbert, C. L., Banks, G. B., Butts, T. M., Finn, E. E., Allen, J. M., Miller, A. D., Chamberlain, J. S., & Tapscott, S. J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2012-08
Volume
20
Issue
8
Pages
1501-1507
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2032902046
Cited by
78
References
10
FWCI
6.02
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Successful Regional Delivery and Long-term Expression of a Dystrophin Gene in Canine Muscular Dystrophy: A Preclinical Model for Human Therapies. https://app.cochat.ai/papers/10.1038/mt.2012.111
The paper
Wang, Z., Storb, R., Halbert, C. L., Banks, G. B., Butts, T. M., Finn, E. E., Allen, J. M., Miller, A. D., Chamberlain, J. S., & Tapscott, S. J. (2012). Successful Regional Delivery and Long-term Expression of a Dystrophin Gene in Canine Muscular Dystrophy: A Preclinical Model for Human Therapies. Molecular Therapy. https://doi.org/10.1038/mt.2012.111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.